Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma

Krisztina Mita Gabor, Z. Sápi, Lilla Gyorgyi Tiszlavicz, Anita Fige, C. Bereczki, Katalin Bartyik

Research output: Contribution to journalArticle

13 Citations (Scopus)


Pseudomyogenic hemangioendothelioma (PMH) is a rare, mostly indolent vascular tumor. Extensive cases are treated with amputation as chemotherapy seems to be ineffective. Recently, promising results were published using mammalian target of rapamycin (mTOR) inhibitors in tumors of vascular origin. Here, we present a case of a child with advanced PMH relapsing after surgery and chemotherapy. Sirolimus achieved significant clinical improvement and stabilization of the lesions without any remarkable toxicity. This case contributes to the growing evidence regarding the efficacy of mTOR inhibitors, such as sirolimus, in multifocal PMH.

Original languageEnglish
Article numbere26781
JournalPediatric Blood and Cancer
Issue number2
Publication statusPublished - Feb 1 2018


  • mTOR inhibition
  • pseudomyogenic hemangioendothelioma
  • sirolimus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma'. Together they form a unique fingerprint.

  • Cite this